Altimmune to Participate at 31st Annual ROTH Conference March 14, 2019 at 9:00 AM EDT PDF Version GAITHERSBURG, Md., March 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief Executive Officer, and Will Brown, Acting Chief Financial Officer, will provide a corporate overview at the 31st Annual ROTH Conference. Details of the presentation are as follows: 31st Annual ROTH Conference Presentation DetailsDate: Tuesday, March 19Time: 1:30pm Pacific TimeLocation: The Ritz Carlton, Laguna Niguel in Orange County, CA About AltimmuneAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is an immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of tumor types. NasoVAX, our influenza vaccine candidate, has unique characteristics that stimulate multiple arms of the immune system and offers the potential to stop infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is a next-generation intranasal anthrax vaccine candidate that is intended to improve protection and safety while having favorable dosage and storage properties compared to other anthrax vaccines. By leveraging the complementary attributes of its proprietary technology platforms, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including both acute and chronic infections and cancer. Contacts:Vipin K. Garg, Ph.D. Ashley RobinsonPresident and CEO Managing Director LifeSci AdvisorsPhone: 919-434-6643 Phone: 617-535-7742Email: firstname.lastname@example.org Email: email@example.com Source: Altimmune, Inc.